TY  - JOUR
TI  - A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera
AB  - Introduction: Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV). Methods: A total of 34 patients with PV from 18 different centers were included in the study. The evaluation of the response under treatment with ruxolitinib was determined as a reduction in spleen volume (splenomegaly size: ≥35%) by imaging and control of hematocrit levels (≤45%) compared to baseline. Results: While the number of patients in which a reduction in spleen volume and hematocrit control was achieved was 19 (55.9%) at 3 months of treatment, it was 21 (61.8%) at 6 months. Additionally, while the number of side effects was negatively correlated with the reduction in spleen volume (Spearman’s rho: -0.365, p=0.034), a decrease in the hematocrit level was positively correlated (Spearman’s rho: 0.75, p=0.029). Those without a reduction in spleen volume experienced more constipation (chi-square: 5.988, Fisher’s exact test: p=0.033). Conclusion: This study shed light on the use of ruxolitinib in PV and the importance of splenomegaly on studies planned with larger patient groups.
AU  - Altuntaş, Fevzi
AU  - Merter, Mustafa
AU  - ERKURT, MEHMET ALI
AU  - AYDOGDU, ISMET
AU  - Demircioğlu, Sinan
AU  - ALBAYRAK, MURAT
AU  - Hacioglu, Sibel
AU  - Doğu, Mehmet Hilmi
AU  - BASTURK, ABDULKADIR
AU  - Ekinci, Omer
AU  - Ersoy Dursun, Fadime
AU  - TOMBAK, ANIL
AU  - SERIN, Istemi
AU  - Akgun Cagliyan, Gulsum
AU  - REİS ARAS, MERİH
AU  - Turgut, Burhan
AU  - BAGCI, METIN
AU  - Korkmaz, Serdal
AU  - SİNAN DAL, MEHMET
AU  - Ulas, Turgay
DO  - 10.4274/imj.galenos.2023.66742
PY  - 2023
JO  - İstanbul Medical Journal
VL  - 24
IS  - 2
SN  - 2619-9793
SP  - 120
EP  - 125
DB  - TRDizin
UR  - http://search/yayin/detay/1179468
ER  -